Navigation Links
Five-Year Data Confirm That Early Treatment with Betaseron(R) at First Sign of Disease Can Delay Progression to MS
Date:9/20/2008

e and Specialty Medicine, which includes Hematology, Oncology and Multiple Sclerosis. The company's aim is to discover and manufacture products that will improve human health worldwide by diagnosing, preventing and treating diseases.

This news release contains forward-looking statements based on current assumptions and forecasts made by Bayer Group management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in our public reports filed with the Frankfurt Stock Exchange and with the U.S. Securities and Exchange Commission (including Form 20-F). The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

(1) MS Freedman, L Kappos, CH Polman, et al. Impact of Early Interferon beta-1b Treatment on Disease Evolution Over 5 Years in Patients with a First Event Suggestive of Multiple Sclerosis. World Congress on Treatment and Research in Multiple Sclerosis 2008.

(2) Kappos L et al. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet 2007 Aug 4; 370(9585): 389-97


'/>"/>
SOURCE Bayer HealthCare Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
2. Five-Year Data From Taxus II Clinical Trial Highlights Safety and Efficacy of Taxus(R) Stent Compared to Bare-Metal Stent
3. Positive Xeloda(R) Five-Year Overall Survival Study Data in the Adjuvant Treatment of Colon Cancer Presented at Leading European Cancer Meeting
4. Positive Five-Year Safety Data for TAXUS(R) Stent Reported in Boston Scientific Trial
5. Five-Year Data Demonstrate Long-Term Efficacy and Safety with ORENCIA(R) (abatacept) in Adults with Rheumatoid Arthritis Who had an Inadequate Response to Methotrexate
6. Study Confirms Limited Human-To-Human Spread of Avian-Flu Virus in Indonesia in 2006
7. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
8. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
9. KineMed Presents Preclinical Data for Investigational Agent Demonstrating Neurogenesis and Confirming Improvements in Behavioral Model
10. New Clinical Studies Confirm Mauna Kea Technologies Cellvizio(R) GI in Range of Procedures
11. IDM Pharma Announces Updated Phase 3 Mifamurtide (L-MTP-PE) Data Confirms Statistically Superior Overall Survival in Osteosarcoma Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)... 2015  SurgiQuest®, Inc. ("SurgiQuest", the "Company"), a ... invasive surgery (MIS) announced today that surgeons have ... procedures.  Adoption has risen rapidly with a 150% ... by the company,s expansion from robotics into the ... to over 45 countries.   The ...
(Date:6/3/2015)... , June 02, 2015 Research and ... of the "Global Neurodegenerative Diseases Market 2015-2019" ... global neurodegenerative diseases market to grow at a ... This report covers the present scenario and ... market for the period 2015-2019. To calculate the ...
(Date:6/3/2015)... 2015  EIP Pharma LLC ( www.eippharma.com ) today ... of VX-745 in Alzheimer,s disease (AD) is underway.  VX-745 ... inhibitor of the alpha isoform of the protein enzyme ... "Recent human genetic data demonstrate that inflammation is ... Alzheimer,s, while the science also indicates the p38 MAPK ...
Breaking Medicine Technology:Rapid Procedure Growth With SurgiQuest's AirSeal System 2Global Neurodegenerative Diseases Market 2015-2019 - Reformulation of Marketed Drugs 2EIP Pharma announces first patient dosing in phase 2 clinical studies of a novel brain-targeted anti-inflammatory drug candidate, VX-745, for the treatment of Alzheimer's disease (AD) 2EIP Pharma announces first patient dosing in phase 2 clinical studies of a novel brain-targeted anti-inflammatory drug candidate, VX-745, for the treatment of Alzheimer's disease (AD) 3
... premier Canadian pharmacy intermediary since 2002, reveals the top ... a Canada pharmacy . 1. Low Prices - ... less than the U.S. price and SaveRxCanada.com has been negotiating the ... – Many patients are elderly and find it difficult to get ...
... 2011 /PRNewswire-Asia/ -- Winner Medical Group Inc. (Nasdaq: ... medical dressings, medical disposables and non-woven fabric made from ... it will release financial results for its second quarter ... Medical,s senior management will host a conference call to ...
Cached Medicine Technology:Canadian Pharmacy Intermediary's Top Reasons U.S. Customers Choose Canada Online Pharmacies Revealed by SaveRxCanada.com 2Winner Medical Group Inc. to Host Second Quarter 2011 Earning Conference Call on Wednesday, May 11, 2011 at 08:30 a.m. EDT 2
(Date:6/3/2015)... Loma Linda University Health and Adventist Health ... Memorial Hospital (SGMH). The SGMH board voted unanimously to ... “Loma Linda University Health has been serving the Pass ... officer, Loma Linda University Medical Center. “We are thrilled ... this community.” , Under the proposed affiliation, Loma ...
(Date:6/3/2015)... The Canton Group, a leading web and ... today that Tim Dodge has joined the company as ... Canton Group as it implements an ambitious growth ... Tim is a tech industry veteran who has developed ... companies. Before joining The Canton Group, Tim was Vice ...
(Date:6/3/2015)... On June 22, 2015, Medicare will begin denying coverage ... that it has reimbursed since 2009. , Payment denial ... the 49 million Medicare beneficiaries in the U.S. who are ... Sadly, if it became a standard of care, this testing ... an individual’s genetic information to tailor treatment, is by all ...
(Date:6/3/2015)... 2015 Horizon Blue Cross Blue Shield of ... one of the nation’s top employers for diverse managers and ... its national list of Best Places for Diverse Managers and ... 1 Regional Company. This is the sixth consecutive year ... for its diverse workplace policies and programs. , Companies are ...
(Date:6/3/2015)... 03, 2015 A group of nine ... with a Global Inspire Award at DIA’s upcoming Annual ... outstanding volunteers for their leadership, level of excellence, and ... , The recipients of the Author(s) of the Year ... whose article has made a significant impact in advancing ...
Breaking Medicine News(10 mins):Health News:Loma Linda University Health and Adventist Health Enter into Exclusive Affiliation Negotiations with San Gorgonio Memorial Hospital 2Health News:The Canton Group Appoints Tim Dodge as Chief Marketing Officer 2Health News:Medicare Limiting Coverage Benefit for Drug Sensitivity Testing on June 22, 2015 2Health News:Medicare Limiting Coverage Benefit for Drug Sensitivity Testing on June 22, 2015 3Health News:Medicare Limiting Coverage Benefit for Drug Sensitivity Testing on June 22, 2015 4Health News:Medicare Limiting Coverage Benefit for Drug Sensitivity Testing on June 22, 2015 5Health News:Medicare Limiting Coverage Benefit for Drug Sensitivity Testing on June 22, 2015 6Health News:Medicare Limiting Coverage Benefit for Drug Sensitivity Testing on June 22, 2015 7Health News:Horizon Blue Cross Blue Shield of New Jersey Named a 2015 Best Place for Diverse Managers and Women to Work by Diversity MBA Magazine 2Health News:Authors Representing TransCelerate BioPharma Inc. to Be Honored with Global Inspire Award at DIA’s 2015 51st Annual Meeting 2Health News:Authors Representing TransCelerate BioPharma Inc. to Be Honored with Global Inspire Award at DIA’s 2015 51st Annual Meeting 3Health News:Authors Representing TransCelerate BioPharma Inc. to Be Honored with Global Inspire Award at DIA’s 2015 51st Annual Meeting 4
... the first long-term randomized trial of a chemopreventive agent for ... cancer in the drug-treated group may be attributable to shrinkage ... The study of the Prostate Cancer Prevention Trial, led by ... Gann, is published in the Sept. 12 issue of the ...
... Providers, SEATTLE, Sept. 12 , News Facts -- ... concerns and interests to the 2008 presidential candidates ... online physician community. -- The initiative is enabling U.S. licensed ... via individual web-based videos. Experts from a ...
... Wrinkles, HIGHLANDS, N.J., Sept. 12 Fifty really ... men in their 40s and 50s look better than,their ... can look incredibly sexy at any age. So ... keep the,attention of handsome himbos and beautiful babes? Biocap, ...
... Corporation,(Nasdaq: KNSY ) today announced that it will ... 30, 2007 at 7:00 A.M. Eastern Time on,Friday, October ... be hosting a teleconference,discussing the earnings results on Friday, ... participate in the teleconference call, dial 1-651-291-5254. The,teleconference call ...
... billion dollars. , But an unhealthy kidney costs moreabout ... associate professor in the division of nephrology and hypertension ... about $17 billion a year to care for patients ... currently over 320,000 people undergoing hemodialysis in the United ...
... Centers Head and Neck Cancer Center is teaming up ... cancer. The clinical alliance between Mount Sinai and ENT ... allergy and audiology practice in the tri-state area, together ... quality care, cancer screening and advanced surgical options for ...
Cached Medicine News:Health News:Shrinkage of prostate led to overestimation of cancer risk in trial 2Health News:U.S. Physicians Question Presidential Candidates 2Health News:Cougars Crave Biocap, The Haute Pepper Wrinkle Eraser 2Health News:Kensey Nash Corporation Announces its First Quarter 2008 Earnings Release Date and Teleconference 2Health News:Clinical trials present better alternatives for dialysis patients 2Health News:Mount Sinai & ENT and Allergy Associates, LLP affiliate to fight cancer 2
... Constructed of optical steel ... electro-plate. Comes with custom ... that create a seal ... for increased scatter radiation ...
... and comfortable eye protection Properly manufactured ... of scatter radiation. Our high quality frames ... comfort with minimized weight. Our lenses are ... that meet all industry standards. Most Pulse ...
... eye protection Properly manufactured radiation protective ... radiation. Our high quality frames and materials ... minimized weight. Our lenses are made of ... all industry standards. Most Pulse Glasses are ...
... Both lenses and frames are designed with the ... Our lenses are Schott RS-520 (also called SF-6) ... glass. These lenses meet standards, as set for ... correction. ,While our eyewear is protecting your ...
Medicine Products: